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Abstract Hemangiomas represent a powerful model to study in
vivo angiogenesis. Monocyte chemotactic protein 1 (MCP-1) is
known to be responsible for recruiting macrophages to sites of
infection or in£ammation and facilitate angiogenesis. Recently
we have demonstrated that edible berry extracts potently sup-
press inducible vascular endothelial growth factor expression
and in vitro angiogenesis. Comparative analysis of several berry
extracts led to the observation that wild blueberry and a berry
mix were most e¡ective. Our goal was to follow up on our
¢ndings with wild blueberry and the berry mix (OptiBerry).
The present work rests on our current ¢nding that these two
berry powders signi¢cantly inhibit inducible MCP-1 expression
in endothelioma cells. Therefore, we sought to examine the ef-
fects of wild blueberry and berry mix in an in vivo model of
experimental angiogenesis. Reporter studies showed that the
berry powders signi¢cantly inhibited basal MCP-1 transcription
and inducible nuclear factor UB transcription. Endothelioma
cells pre-treated with berry powders showed diminished ability
to form hemangioma. Histological analysis demonstrated mark-
edly decreased in¢ltration of macrophages in hemangioma of
treated mice compared to placebo-treated controls. The current
results provide the ¢rst in vivo evidence substantiating the anti-
angiogenic property of edible berries.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Hemangiomas are the most common tumor of infancy oc-
curring in approximately 1:100 normal newborns, but in pre-
mature infants weighing less than 1000 g the incidence rises to
1:5 live births [1]. The hemangioma is characterized by rapid
growth during the ¢rst year of life (proliferative phase) fol-
lowed by a decline in growth (involutional phase) over the
next 5^6 years, with complete regression of the lesion in
90% of a¡ected individuals by age 9 (the involuted phase).
The stimuli responsible for initiating, maintaining and inhib-
iting the endothelial cell growth in hemangiomas have not
been identi¢ed. Although 90% of these lesions spontaneously
regress, 5% of hemangiomas cause serious tissue damage and
approximately 1^2% of all hemangiomas are life threatening.
Proliferating hemangiomas are highly angiogenic with urinary
basic ¢broblast growth factor levels present in the urine of
a¡ected individuals at 25^50-fold levels above normal controls
[2]. Hemangiomas arise from clonal expansion of a single
endothelial cell precursor [3]. The presence of macrophages
is associated with proliferating hemangiomas, but not involut-
ing hemangiomas [4], and the signi¢cance of this association
remains unexplained.
The CC chemokine monocyte chemotactic protein 1 (MCP-
1) is known to be responsible for recruiting macrophages to
sites of infection or in£ammation. In this way, MCP-1 could
be viewed as a major accessory facilitating angiogenesis. Re-
cently, a direct role of MCP-1 on angiogenesis has been also
evident [5]. MCP-1 induced chemotaxis of human endothelial
cells at nanomolar concentrations. This chemotactic response
was inhibited by a monoclonal antibody to MCP-1. MCP-1
also induced the formation of blood vessels in vivo. More-
over, the direct e¡ect of MCP-1 on angiogenesis was consis-
tent with the expression of CCR2, the receptor for MCP-1, on
endothelial cells. It was thus suggested that antagonists of
MCP-1 should prove to be anti-angiogenic [5].
Nutrition is a major tool in health preservation and disease
prevention. The therapeutic property of edible berries has
been long known [6]. More recently, it has been observed
that edible berries may have potent chemopreventive proper-
ties [7^11]. Berries are rich in anthocyanins, £avonoid glyco-
sides responsible for the red, violet, purple and blue color of
the fruit. Dietary consumption of anthocyanin has been
shown to improve overall antioxidant defense status of human
plasma [12]. On one hand, the search is on for speci¢c medical
drugs that would e⁄ciently limit angiogenesis [13,14]. On the
other hand, diet-based approaches to limit angiogenesis are
being actively explored [7,8,15^20]. Proven safety for human
use is a major merit that strengthens this latter approach.
While it is evident that consumption of a plant-based diet
can prevent the development and progression of disorders
associated with extensive neovascularization [15], the under-
lying mechanisms remain unclear. Vascular endothelial
growth factor (VEGF)/vascular permeability factor plays a
crucial role in angiogenesis. Recently we have demonstrated
that edible berry extracts including OptiBerry potently sup-
press inducible VEGF expression and in vitro angiogenesis
[21]. Analysis of several berry extracts led to the observation
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that wild blueberry and a berry mix were most e¡ective in
inhibiting inducible VEGF expression. These extracts also
had the highest antioxidant function as determined by the
oxygen radical absorbing capacity [21]. Our goal was to fol-
low up on our ¢ndings with wild blueberry and berry mix.
The present work rests on our current ¢nding that these two
berry extracts signi¢cantly inhibit inducible MCP-1 expression
in endothelioma cells. Therefore, we sought to examine the
e¡ects of wild blueberry and berry mix (OptiBerry) in an in
vivo model of experimental angiogenesis.
2. Materials and methods
2.1. Materials
Wild blueberry and berry powder mix (Mix 1 [21] OptiBerry IH141)
were obtained from InterHealth Nutraceuticals (Benicia, CA, USA).
Unless otherwise stated all other chemicals and reagents were ob-
tained from Sigma Chemical (St. Louis, MO, USA) and were of
analytical grade or the highest grade available.
2.2. Cells and cell culture
Endothelioma (EOMA) cell line was originally derived from a spon-
taneously arising hemangioendothelioma in the 129/J strain [22]. To
perform MCP-1 enzyme linked immunosorbent assays (ELISA), £ow
cytometer propidium iodide assays, MCP-1 and nuclear factor UB
(NF-UB) luciferase assays, EOMA cells were seeded at 1.5U105
cells/ml density in 6 well plates in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% fetal bovine serum, penicillin (100 U/
ml), and streptomycin (100 Wg/ml) at 37‡C in a humidi¢ed atmosphere
containing 95% air and 5% CO2 as previously described [23]. Follow-
ing 24 h incubation, the culture medium was replaced with fresh
medium. Wild blueberry and berry mix powders were added at 50
Wg/ml (in dimethyl sulfoxide (DMSO)) as described previously [21].
Cells in the control group were treated with the same volume (0.01%
v/v) of DMSO.
2.3. MCP-1 ELISA assay
Following 24 h of seeding of EOMA cells, the culture medium was
replaced with fresh medium and the cells were treated with berry
powder as described above for 12 or 24 h. After such treatment, cells
were activated with tumor necrosis factor K (TNFK, 400 IU/ml) for
12 h. MCP-1 levels in cell-free culture media were measured using
commercially available ELISA kit (RpD Systems) according to the
manufacturer’s instructions as previously described [23]. Results were
normalized to total protein concentration measured from cell lysates.
2.4. Luciferase reporter assay
EOMA cells were transiently transfected with the MCP-1-Luc or
NF-UB-Luc constructs using E¡ectene (Invitrogen) reagent according
to the manufacturer’s instructions. For MCP-1 luciferase assay, cells
were transiently transfected with the MCP-1 distal enhancer plus
proximal promoter construct attached to the luciferase encoding re-
gion as described previously [24]. After 24 h of transfection, cells were
treated for 24 h with the respective berry powders as indicated in the
¢gure legends. For NF-UB-Luc assay, cells were activated with TNFK
for 6 h as described above. Luciferase activity was determined using a
commercial kit (Stratagene).
2.5. Cell viability assay £ow cytometry
Cell membrane integrity was also monitored by £ow cytometry
(EPICS Elite or XL, Coulter) as a measure of cell viability. For this
assay, the non-permeant DNA intercalating dye propidium iodide
(Molecular Probes) was used. This dye is excluded by viable cells. A
15 mW powered argon ion laser was used for excitation at 488 nm,
and the emission signal was collected at 575 nm as described earlier
[25].
2.6. Generation of hemangiomas
There are two murine models of hemangioma. One model uses
endothelial cells transformed with the oncogenic middle T antigen
of the murine polyoma virus [26,27] and the other model uses endo-
thelial cells from a spontaneously arising hemangioendothelioma (a
clinical subtype of hemangioma). Either cell line can be injected sub-
cutaneously to generate hemangiomas. We have chosen to use the
EOMA cell line derived from the spontaneously arising hemangioma
for several reasons. The polyoma transformed cell lines have been
reported to create tumors by recruiting host cells [28]. EOMA cells
were derived from a 129 P/3 strain, which has an H-2b MHC back-
ground, while the other cell line is derived from a B/6UDBA/2 F2
hybrid, giving it a mixed H-2b and H-2d MHC background limiting
its use in vivo to nude or SCID mice. The EOMA cell line has also
been well characterized in the literature with regard to its derivation
[22], expression of endothelial cell markers [29], ability to induce Ka-
sabach^Merritt syndrome [30,31], production of endostatin [32^
34]and response to angiostatin [35].
EOMA cells were prepared for injection as described previously
[23]. The cells were grown in 175 cm2 tissue culture £asks in the
conditions mentioned above, and were trypsinized when they reached
V85% con£uence. The cells were washed three times in large volumes
(50 ml) of phosphate bu¡ered saline, pH 7.4 (PBS), counted and
resuspended in PBS at 5U107 cells/ml and kept on ice. The cell sus-
pension was loaded into a 1 cc insulin syringe with 28 gauge needle
(Becton Dickinson, Franklin Lakes, NJ, USA) to a ¢nal volume of
100 Wl per syringe. 129 P3 mice from Jackson Laboratories (Bar
Harbor, ME, USA) are syngeneic with the EOMA cells. Eight week
old mice received inhalation anesthesia and were injected subcutane-
ously with 100 Wl of cell suspension for a total dose of 5U106 cells.
Tumor was harvested 1 week after the injection. After weighing and
scaled digital photography, the samples were treated with OCT re-
agent for frozen sections. All animal protocols were approved by the
Animal Institutional Laboratory Animal Care and Use Committee
(ILACUC) of the Ohio State University, Columbus, OH, USA.
2.7. Histology
Freshly dissected, un¢xed hemangioma specimens were snap-frozen
and immediately cut into 10 Wm frozen sections. Endogenous peroxi-
dase activity was blocked with 0.3% (v/v) H2O2 in Tris bu¡ered saline
(TBS). The slides were washed three times with TBS. Before addition
of primary antibody, tissue non-speci¢c binding was blocked using
serum-free protein block (Dako, Glostrup, Denmark) for 15 min.
After three washes in TBS, the slides were incubated for 60 min
with rat anti-mouse CD11b (1:200 dilution; Chemicon International,
Temecula, CA, USA). To con¢rm macrophage speci¢city of stains,
other sections were incubated for 60 min with rat anti-mouse F4/80
(1:50 dilution; Serotec, Raleigh, NC, USA). Next, the slides were
washed with TBS and blocked in avidin and biotin solutions
(Dako) for 20 min each prior to the secondary antibody. Biotinylated
rabbit anti-rat (Vector) secondary antibody in 3% mouse serum was
incubated for 30 min. Slides were washed with TBS and incubated
with streptavidin^horseradish peroxidase complex (Dako) for 15 min.
After three washes, slides were incubated with substrate-chromogen
solution (3,3P-diaminobenzidine, Dako) for 5 min and counterstained
with Mayer hematoxylin for 3 min. The slides were then mounted
with Gel Mount (Biomeda). Digital images were obtained using a
motorized Zeiss Axiovert 200 microscope ¢tted with color Axiocam
camera and Axiovision 4.0 software.
2.8. Statistical analysis
In vitro data are reported as meanRS.D. of three experiments each
conducted in triplicate. Comparisons between berry treated groups
and control samples were done using independent samples t-test.
P6 0.05 was considered statistically signi¢cant.
3. Results
TNFK is a potent inducer of MCP-1 in EOMA cells. Pre-
treatment of cells with both berry powders signi¢cantly de-
creased inducible MCP-1 expression. Two durations of pre-
treatment, 12 h and 24 h, were tested. It was evident that the
e¡ect of berry powders on inducible MCP-1 expression did
not change with increased duration of treatment. Inducible
MCP-1 protein was signi¢cantly lower than the control group
in both 12 and 24 h pre-treatment groups (Fig. 1). To verify
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that the berry powders did not have any cytotoxic property at
the concentrations used, cells were treated with the berry pow-
ders either at test concentrations or in excess. Flow cytometric
analysis of cell membrane integrity showed that under stan-
dard culture conditions less than 5% of the total cells stained
with propidium iodide indicating lost viability. When treated
with berry powders at test concentrations, no further loss of
cell viability was detected. These observations con¢rm our
previous observation that these berry powders are not toxic
to cells at the tested concentrations [21]. However, treatment
of EOMA cells with a ¢ve-fold excess of berry powders in-
duced cell death. Under these conditions, the proportion of
dead cells in the suspension tripled to approximately 15%
(Fig. 2). It is therefore reasonable to interpret that the re-
ported e¡ects of berry powders in this study are not related
to general cytotoxicity of the powders. The observation that
high concentrations of berry powder induce cell death is con-
sistent with the demonstrated pro-apoptotic e¡ects of natural
£avonoids [36].
Transfection of EOMA cells with a MCP-1 luciferase re-
porter construct resulted in high baseline luciferase activity
suggesting elevated levels of basal MCP-1 transcription in
this EOMA cells. Pre-treatment of cells with both berry pow-
ders signi¢cantly lowered basal MCP-1-luciferase reporter ac-
tivity (Fig. 3). This observation suggests that the berry pow-
ders inhibited basal MCP-1 transcription in EOMA cells.
MCP-1 transcription is mediated by several transcription fac-
tors among which NF-UB is a key player [37]. Therefore, we
sought to examine whether inducible NF-UB transcription is
regulated by the tested berry powders. As expected, TNFK
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Fig. 1. MCP-1 protein expression. EOMA cells were treated with
wild blueberry or berry mix powder for 12 or 24 h prior to TNFK
treatment. MeanRS.D. *P6 0.05, **P6 0.01, lower compared to
untreated cells for the e¡ect of berry treatment on TNFK induced
MCP-1 expression.
Fig. 2. E¡ect of berry powders on cell viability. Flow cytometric
propidium exclusion assay for viability. MeanRS.D. *P6 0.05, sig-
ni¢cant toxic e¡ect of berry powder treatment was seen at 250 Wg/
ml but not at 50 Wg/ml.
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Fig. 3. MCP-1 reporter assay. MCP-1-Luc reporter constructs were
transiently transfected in EOMA cells. After 24 h of transfection,
the cells were treated with wild blueberry or berry mix powders for
24 h. MeanRS.D. *P6 0.05, **P6 0.01, lower compared to un-
treated cells for the e¡ect of berry treatment.
Fig. 4. NF-UB reporter assay. NF-UB-Luc reporter construct was
transiently transfected in EOMA cells. After 24 h of transfection,
the cells were treated with wild blueberry or berry mix powders for
24 h. Subsequently cells were activated using TNFK for 6 h.
MeanRS.D. *P6 0.05, lower compared to untreated cells for the ef-
fect of berry treatment.
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potently induced NF-UB transcription. Inducible NF-UB ac-
tivity was signi¢cantly lower in EOMA cells pre-treated with
berry extracts (Fig. 4). These results provide ¢rst evidence that
inducible NF-UB in EOMA cells is subject to regulation by
berry constituents.
Next, our goal was to test the functional signi¢cance of our
¢ndings in an in vivo setting. To accomplish this objective,
EOMA cells were either treated or not with berry powders
prior to being injected into mice. Subcutaneous injection of
EOMA cells in mice results in the rapid formation of heman-
gioma in 100% of the cases. Histological examination of these
hemangiomas revealed massive macrophage in¢ltration as de-
tected by CD11b as well as F4/80 staining. As indicated in a
later section, injection of EOMA cells pre-treated with berry
powder did not result in hemangioma formation in all mice.
In cases where a hemangioma was visible, histological analysis
clearly demonstrated that macrophage in¢ltration in such
hemangioma was markedly diminished (Fig. 5). This e¡ect
was consistently observed in all mice. A total of 36 mice
were injected with EOMA cells in this study. As illustrated
in Fig. 6, 100% of the controls, 47% of the wild blueberry
treated group, and 92% of the berry mix treated group tested
positive for the presence of a hemangioma. Of importance,
although the treated group did test positive for the presence
of hemangioma the average mass of such growth was below
50% of the average growth observed in the untreated control
group. In the wild blueberry treated group, the absence of
hemangioma in over 50% of the cases is indeed remarkable.
Fig. 5. Immunohistochemical localization of macrophages in hemangioma. Sections were collected 1 week after subcutaneous injection of either
untreated (treated with DMSO vehicle at 0.01% v/v, a) or wild blue berry (b) or berry mix (c) treated EOMA cells to 129 P3 mice. Sections
counterstained with Mayer hematoxylin for contrast. Dark (brown) spots represent macrophages. Representative samples shown. CD11b (top;
a1^c1) or F4/80 (bottom; a2^c2) staining was performed to detect macrophages as described in Section 2. CD11b stains are CD3 and CD8
negative. 10U.
Fig. 6. Hemangioma mass, incidence and appearance. Data collected
1 week after subcutaneous injection of wild blueberry or berry mix
treated or untreated (control) EOMA cells to 129 P3 mice.
MeanRS.D. **P6 0.01, lower mass compared to control group.
See Section 2 for details. Photo: top, control; middle, blueberry
treated, case of no hemangioma shown, injected cells seen at the
center; bottom, berry mix treated. See bar graph for average mass
of hemangioma. Scale= 1 inch.
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4. Discussion
Folkman described hemangiomas as a relatively pure form
of angiogenesis [1]. Injected EOMA cells proliferate to form
blood vessel conduits that anastomose with the general circu-
lation to draw blood into the hemangioma. This results in
erythrocyte sequestration and rapid fall of hematocrit. Mice
typically succumb to a disorder clinically referred to as Ka-
sabbach^Meritt syndrome [38] within 3^4 weeks of EOMA
injection. In addition to its clinical relevance, the EOMA
model of angiogenesis o¡ers the following advantages as an
experimental system. First, injection of EOMA cells results in
tumor production in days with 100% e⁄ciency resulting in
quick reliable in vivo data generation. Second, EOMA cells
can be pharmacologically or genetically treated in vitro to
study the e¡ects of variable manipulation on endothelial cell
behavior in vitro. Finally, manipulating these cells in vitro
followed by injection in vivo provides an e⁄cient unique mod-
el to study the in£uence of tumor cell derived signals that
regulate angiogenesis through the recruitment of host endo-
thelial cells.
The ability of macrophages to in£uence angiogenesis has
been recognized for many years beginning with experiments
that showed cultured supernatants from macrophages could
stimulate angiogenesis in vitro [39^41]. There is indirect evi-
dence in clinical situations to support this notion. For exam-
ple, wound healing is an angiogenic process that fails to occur
without the assistance of macrophages [42]. A direct correla-
tion has been documented between the presence of tumor
associated macrophages and vascularity in breast cancer speci-
mens and mortality [43^47], the implication being that the
presence of macrophages facilitates the angiogenic processes
of the tumor thereby promoting metastases. Macrophages
have also been proposed to play a role in vasculogenic mimi-
cry, the creation of non-endothelial lined channels emanating
from tumors, such as melanoma, that contain red blood cells
or shed tumor cells and are associated with aggressive tumor
behavior and high mortality [48,49]. Despite the plethora of
circumstantial evidence, the mechanisms and extent of macro-
phage involvement in the angiogenesis-dependent tumor pro-
liferation process are not well de¢ned.
Macrophages have been shown to produce many growth
factors and cytokines known to participate in the regulation
of angiogenesis [50^52] and Polverini and Leibovich have even
shown that tumor associated macrophages are angiogenic
[40]. Furthermore, our recent studies demonstrate that macro-
phage derived reactive species support angiogenesis [53^55].
Our ¢ndings are consistent with previous data showing that
treatment of macrophage cultures with oxygen free radical
scavengers substantially inhibits the angiogenic activity of
conditioned media in rat corneal angiogenesis assays [50]. Ac-
tivated macrophages co-cultured with bovine aortic endothe-
lial cells (BAECs) grown on type I collagen gels are known to
induce branching/sprouting behavior in the BAECs indicative
of angiogenic behavior. This sprouting behavior was signi¢-
cantly inhibited by catalase suggesting an angiogenic role of
H2O2 [56]. We have previously reported that hemangioma is
characterized by footprints of oxidative stress suggesting in-
volvement of elevated levels of reactive oxygen species [23].
More recently it has been shown that oxidants drive MCP-1
expression [57]. Indeed redox-sensitive transcription factors
such as NF-UB and AP-1 [58^60] regulate inducible MCP-1
expression [37,61]. Our results show that treatment of cells
with both berry extracts, blueberry and OptiBerry, inhibits
inducible NF-UB transcription. Pharmacokinetic studies ad-
dressing the absorption of dietary berry constituents support
the relevance of our ¢ndings [12,62]. Given that inducible NF-
UB activation is sensitive to antioxidants [58^60] and that the
berry powders tested are known to be rich in antioxidant
activity [21] it is plausible that the observed e¡ect of berries
on inducible NF-UB activation and MCP-1 expression is de-
pendent on their antioxidant property. Berry phenolics, espe-
cially anthocyanins, are primarily responsible for their anti-
oxidant property [63].
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